Circulating MicroRNAs as Novel Potential Biomarkers for Left Ventricular Remodeling in Postinfarction Heart Failure

Table 2

Baseline characteristics of the subjects.

Variable	Control ()	Postinfarction HF ()
Age (years)^Ɨ	61.1 (12.4)	62.4 (10.2)
Female^¶	9 (56.3)	17 (53.1)
Diabetes^¶	4 (25.0)	10 (31.3)
Hypertension^¶	8 (50.0)	15 (46.9)
Current smoker^¶	3 (18.8)	5 (15.6)
Triglycerides (mmol/l)^Ɨ	1.92 (1.62)	1.58 (1.02)
Total cholesterol (mmol/l)^Ɨ	4.47 (1.81)	4.00 (1.00)
LDL (mmol/l)^Ɨ	2.65 (1.13)	2.54 (0.89)
HDL (mmol/l)^Ɨ	1.20 (0.26)	1.05 (0.21)
Creatinine (μmol/l)^Ɨ	73.47 (11.20)	84.47 (14.82)
β-Receptor blockers^¶	4 (25.0)	18 (56.3)
ACE inhibitors or AR blockers^¶	5 (31.3)	20 (62.5)
NT-proBNP (pg/ml)^§	99.1 (71.5, 132.8)	831.0 (152.5, 1605.0)
Echocardiography
LVIDd (mm)^Ɨ	42.6 (2.3)	54.1 (7.7)
LVEDV (ml)^Ɨ	105.4 (34.6)	159.9 (65.4)
Ejection fraction (%)^Ɨ	73.2 (3.7)	44.5 (9.4)
Fractional shortening (%)^Ɨ	42.0 (2.8)	21.3 (5.6)
IVS (mm)^Ɨ	9.5 (1.9)	10.3 (1.6)
LVPW (mm)^Ɨ	9.5 (1.8)	9.8 (1.2)

^ƗMean (SEM), no. (%), and ^§median (25% percentile, 75% percentile) of nonnormally distributed variables. HF: heart failure; LDL: low-density lipoprotein cholesterol; HDL: high-density lipoprotein cholesterol; ACE: angiotensin-converting enzyme; AR: angiotensin receptor; NT-proBNP: N-terminal pro-B type natriuretic peptide; LVIDd: left ventricular internal end diastolic dimension; LVEDV: left ventricular end diastolic volume; IVS: interventricular septum; LVPW: left ventricular posterior wall. versus controls.